IP Library Granted Patent US 8,703,485
Granted Patent B2
US 8,703,485 · App. 12/130,818 · Granted Apr 22, 2014

Germ cells having inactivated endogenous immunoglobulin genes, and transgenic animals derived therefrom

Inventor: Roland Buelow (Palo Alto, CA)
Assignee: OMT, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,703,485
App. No.
12/130,818
Granted
Apr 22, 2014
Kind
B2
Abstract

The invention relates to transgenic animals lacking endogenous Ig and capable of producing transgenic antibodies, as well as methods of making the same. The invention further relates to methods for producing transgenic antibodies in such animals, and transgenic antibodies so produced.

Claims (14)

1. A viable rodent germ cell having at least one endogenous immunoglobulin (Ig) gene inactivated by the action of at least one meganuclease.

2. A transgenic rodent comprising the viable rodent germ cell of claim 1 .

3. The viable rodent germ cell of claim 1 , further comprising an artificial Ig gene comprising a human immunoglobulin (Ig) gene segment.

4. A transgenic rodent comprising the viable rodent germ cell of claim 3 .

5. The transgenic rodent according to claim 2 or 4 , wherein said endogenous Ig gene is an Ig light chain gene.

6. The transgenic rodent according to claim 2 or 4 , wherein said endogenous Ig gene is an Ig heavy chain gene.

7. The transgenic rodent of claim 4 , wherein said artificial Ig gene is capable of undergoing productive gene rearrangement to produce immunoglobulins having human idiotypes.

8. The transgenic rodent of claim 4 , wherein the inactivated endogenous Ig gene is an Ig light chain gene and the artificial Ig gene is an Ig heavy chain gene, and wherein said transgenic rodent is capable of producing heavy chain-only antibodies.

9. The transgenic rodent of claim 8 , wherein said artificial Ig gene is a heavy chain Ig constant (C)-region gene lacking a functional CH1 domain.

10. The viable rodent germ cell of claim 3 , wherein said human Ig gene segment comprises a human Ig variable (V) gene segment.

11. The viable rodent germ cell of claim 1 , wherein said inactivated endogenous immunoglobulin gene is an immunoglobulin joining (J) gene.

12. The viable rodent germ cell of claim 1 , wherein said inactivated endogenous immunoglobulin gene is an immunoglobulin constant (C) region gene.

13. The viable rodent germ cell of claim 12 , wherein said immunoglobulin constant region gene encodes immunoglobulin μ.

14. A transgenic rodent comprising the viable germ cell of any one of claims 10 - 13 .

Assignments (4)
CHANGE OF NAME Recorded Nov 16, 2022
From: OMNIAB, INC.
To: OMNIAB OPERATIONS, INC.
Reel/Frame 061952/0838 →
CHANGE OF NAME Recorded Mar 17, 2022
From: OPEN MONOCLONAL TECHNOLOGY, INC.
To: OMNIAB, INC.
Reel/Frame 059435/0056 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY: OMT, INC. PREVIOUSLY RECORDED ON REEL 021058 FRAME 0476. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 18, 2016
From: BUELOW, ROLAND, PH.D
To: OPEN MONOCLONAL TECHNOLOGY, INC.
Reel/Frame 040647/0980 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2008
From: BUELOW, ROLAND, PH.D
To: OMT, INC.
Reel/Frame 021058/0476 →
Continuity (3)
Provisional Application 60941619 · Jun 1, 2007
Provisional Application 61044324 · Apr 11, 2008
Related Publication 20090098134A1 · Apr 16, 2009